MERCK & CO., INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 131.1 USD | +0.00% |
|
+0.18% | +20.27% |
| May. 15 | Transcript : Merck & Co., Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 01:40 PM | |
| May. 15 | Merck to present new oncology data | CF |
Presenter SpeechJaspreet Kaur Nandra (Attendees)Hello, and welcome to our virtual event, a pan...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
2024-05-28
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
131.1
USD
Average target price
141.6
USD
Spread / Average Target
+8.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.27% | 332B | |
| +39.64% | 723B | |
| +34.28% | 595B | |
| -4.20% | 369B | |
| +2.72% | 282B | |
| +17.02% | 244B | |
| +9.31% | 208B | |
| -5.07% | 205B | |
| -0.02% | 168B | |
| +7.31% | 166B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Transcript : Merck & Co., Inc. - Special Call
